2024-07-22T09:46:56-05:00 2023-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2023-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET 9TH FL NEW YORK NY 10004 LOUIS D SCHWARTZ CFAO 2128471111 2024-07-22 1 LOUIS SCHWARTZ 999009999 0 RICHARD J LOCASTRO CPA P00288314 3019519090 3 AAL1 IAL1 2023 2023-04-26 12:10:37Z IAVI MARK B FEINBERG 125 BROAD STREET 9TH FL NEW YORK NY 10004 153956867 0 X WWW.IAVI.ORG X 1996 DE TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS 14 13 268 13 0 0 143987755 124587673 2569928 2297276 -178814 2762423 403411 31028 146782280 129678400 30303444 31255891 0 0 44464122 48531593 0 0 258570 56421196 53108753 131188762 132896237 15593518 -3217837 128948484 124233943 62681430 60310191 66267054 63923752 X A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, EMERGING INFECTIOUS DISEASES, AND NEGLECTED DISEASES. 0 0 112549400 31255891 2297276 RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE THAT RECENTLY YIELDED PROMISING RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, MARBURG, EBOLA SUDEN, AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS. 112549400 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 X 100 0 1 268 1 0 1 IN KE SF UK 0 0 0 0 0 0 0 0 0 0 X 14 13 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X X LAKHERAM SUKHDEO 2127635462 125 BROAD STREET 9TH FL NEW YORK NY 10004 MARK B FEINBERG PRESIDENT/CEO 35.00 X X 719151 0 110715 ERIC PAUL GOOSBY BOARD CHAIR 2.00 X X 0 0 0 ROBERT GOLDBERG BOARD TREASURER 2.00 X X 0 0 0 LINDA-GAIL BECKER BOARD MEMBER 1.00 X 0 0 0 DAVID BLUMBERG BOARD MEMBER 1.00 X 0 0 0 JIM CONNOLLY BOARD MEMBER 1.00 X 0 0 0 MARK DYBUL BOARD MEMBER 1.00 X 0 0 0 WAFAA EL-SADR BOARD MEMBER 1.00 X 0 0 0 ALEXIS M PINTO BOARD MEMBER 1.00 X 0 0 0 JOHN W SHIVER BOARD MEMBER 1.00 X 0 0 0 SUSAN SILBERMANN BOARD MEMBER 1.00 X 0 0 0 ANNE MARTIN SIMONDS BOARD MEMBER 1.00 X 0 0 0 RAJEEV VENKAYYA BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 35.00 X 531087 0 79268 LOUIS D SCHWARTZ ASST. SEC. & CFAO 35.00 X 390586 0 76520 MIN DING GEN. COUNS. & SEC. 35.00 X 333986 0 71843 MARIO GAGLIANO CPO, VP OF HR (FROM 9/23) 35.00 X 102045 0 14230 SWATI GUPTA VP, HEAD OF EID & EPIDEM. 35.00 X 379201 0 76490 DAGNA LAUFER VP & HEAD OF CLINICAL DEV. 35.00 X 394188 0 41148 CHRISTOPHER PARKS - ASSOC AVP. VIRAL VAC. & HEAD OF DDL 35.00 X 365204 0 62119 ERIC SKJEVELAND VP, BUSINESS DEVELOPMENT 35.00 X 341395 0 36715 SANGEETHA SAGAR VP & HEAD OF PRODUCT DEV 35.00 X 376047 0 33504 FRANCES SINHA FORMER OFFICER 35.00 X 105000 0 0 4037890 0 602552 143 1 1 0 EMMES CORPORATION 401 N WASHINGTON ST STE 700 ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 1245043 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 587 CRAIGIEBURN VICTORIA AS 3064 REGULATORY CONSULTANT 401508 WITS HEALTH CONSORT 31 PRINCESS OF WALES TER PARKTOWN JOHANNESBURG AS 02193 PROGRAM CONSULTANT 267425 ARMSTRONG TEASDALE 2005 MARKET STREET SUITE 2900 PHILADELPHIA PA 191034196 LEGAL SERVICES 241508 US MEDICAL EQUIP CONS INC 5601 NW 72ND ST 324 OKLAHOMA CITY OK 73132 EQUIPMENT MAINTENANCE 219338 13 70009700 54577973 124587673 CONTRACT SERVICE FEES 900099 1922276 1922276 RESEARCH & DEVELOPMENT 900099 375000 375000 2297276 3256766 3256766 23784124 24278467 -494343 -494343 -494343 MISCELLANEOUS 900099 31028 31028 31028 129678400 2297276 0 2793451 9318320 9318320 21937571 21937571 2429430 151978 2277452 105000 105000 36453779 25840589 10598058 15132 2954957 2117251 836597 1109 4068743 2787146 1280146 1451 2519684 1683262 835548 874 1090452 258674 831778 215651 215651 225000 225000 89219 89219 798898 60000 738898 850783 512843 337940 1572404 1206462 365942 5859423 5268900 590523 1911741 1609217 300881 1643 404539 348430 56109 1545566 1468855 76711 410686 301444 109242 RESEARCH&CLINICAL SVCS 31039846 30731454 308392 LAB SUPPLIES/EQUIPMENT 5293070 5293070 UNALLOWABLE COSTS 1138668 1083411 55257 EQUIPMENT MAINT. 367321 339834 27487 295486 230689 51436 13361 132896237 112549400 20088267 258570 29030740 34403229 53415955 46434558 472428 279535 613872 146763 47610615 46683234 2254328 927381 31756089 33407409 11405072 8635068 128948484 124233943 7733196 9420265 13914391 11781746 27962390 28968880 13071453 10139300 62681430 60310191 X 35250334 32056013 31016720 31867739 66267054 63923752 128948484 124233943 X -3217837 -39593 914128 X 0 1 X 1 1 1 X 84811837 88668597 124414676 143987755 124587673 566470538 84811837 88668597 124414676 143987755 124587673 566470538 144053796 422416742 1171355 741488 613689 751530 3256766 6534828 1207878 226173 171107 403411 31028 2039597 575044963 14462623 0.73460 0.72490 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: RE TAXES REFUND - 2019 AMOUNT: $ 30,000. OTHER INCOME - 2019 AMOUNT: $ 49,560. 2020 AMOUNT: $ 114,697. 2021 AMOUNT: $ 103,555. 2022 AMOUNT: $ 403,411. 2023 AMOUNT: $ 31,028. LOAN FORGIVENESS - 2019 AMOUNT: $ 59,169. 2020 AMOUNT: $ 63,601. 2021 AMOUNT: $ 67,552. ASSET TRANSFER CREDIT - 2019 AMOUNT: $ 942,000. 2020 AMOUNT: $ 47,875. BANK CREDIT - 2019 AMOUNT: $ 127,149. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 225000 225000 132582018 132807018 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 257550 247500 247500 225000 977550 250000 250000 250000 250000 1000000 1500000 20019070 19833701 185369 27591545 26849533 742012 927381 SECURITY DEPOSITS 317706 LOAN & EXCHANGE 7496 RIGHT-OF-USE ASSETS 8309866 8635068 OPERATING LEASE LIABILITIES 9757974 DEFERRED COMPENSATION PAYABLE 381326 10139300 129543354 -39593 137441 97848 129445506 89219 143675 232894 129678400 132351275 7566577 7566577 124784698 89219 8022320 8111539 132896237 PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. 35,848. REVENUE OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. 64,515. REVENUE OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. 27,508. REVENUE OF IAVI-AFRICA, INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. 9,570. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 143,675. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. 2,162,826. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. 182,079. EXPENSES OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. 3,051,888. EXPENSES OF IAVI-AFRICA, INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. 2,169,784. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY GRANT EXPENSES, ELIMINATED IN CONSOLIDATED AUDIT REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 8,022,320. 1 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 7032126 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 758400 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 14147045 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2235165 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 917931 EUROPE 1 15 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 6729061 SOUTH ASIA 1 25 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 751475 SUB-SAHARAN AFRICA 1 38 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 689540 3 78 0 0 3 78 33260743 0 33260743 EUROPE VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 1143449 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 9393 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 125000 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 1057515 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 220000 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 140666 WIRE TRANSFER 0 EUROPE VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 3186672 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 384200 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 765230 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 10826 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 326982 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 129373 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 76941 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 10567 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 10986 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 55148 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 92244 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 25109 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 8965 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1274962 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 250592 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1505455 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 831908 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 980580 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 18363 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 186512 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1539027 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1091036 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1457610 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 55744 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 163608 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 99675 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 2465947 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 2226026 WIRE TRANSFER 0 30 4 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS ARE PERFORMED BY A COMPLIANCE OFFICER LOCATED IN EAST AFRICA. ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. 1 THE SCRIPPS RESEARCH INSTITUTE - OSP 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 3088050 0 RESEARCH & DEVELOPMENT TEXAS BIOMEDICAL RESEARCH INSTITUTE 8715 W MILITARY DR SAN ANTONIO TX 78227 741109630 501(C)(3) 1667115 0 RESEARCH & DEVELOPMENT LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501(C)(3) 592672 0 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 462130 0 RESEARCH & DEVELOPMENT THE UNIVERSITY OF TEXAS MEDICAL BRANCH GALVESTON 301 UNIVERSITY BLVD GALVESTON TX 77555 746000949 501(C)(3) 453031 0 RESEARCH & DEVELOPMENT BOSTON UNIVERSITY TRUSTEES OF BOSTON UNIVERSITY 881 COMMONWEALTH AVENUE BOSTON MA 02115 042103547 501(C)(3) 432798 0 RESEARCH & DEVELOPMENT LSB RESEARCH GROUP LLC 113 N ROBINSON STREET MILES TX 76861 752698571 OTHER 401699 0 RESEARCH & DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910961784 501(C)(3) 270413 0 RESEARCH & DEVELOPMENT NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 250000 0 RESEARCH & DEVELOPMENT 10X GENOMICS INC 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 455614458 OTHER 243904 0 RESEARCH & DEVELOPMENT CLINICAL TRIALS OF TEXAS LLC 5430 FREDERICKSBURA RD STE 200 SAN ANTONIO CA 78229 743019076 501(C)(3) 194767 0 RESEARCH & DEVELOPMENT THE POPULATION COUNCIL INC ONE DAG HAMMARSKJOLD PLAZA 3RD FLOOR NEW YORK NY 10017 131687001 OTHER 146260 0 RESEARCH & DEVELOPMENT TRUSTEES OF TUFTS COLLEGE AKA TUFTS UNIVERSITY 169 HOLLAND STREET ATTN TAX DEPT SOMERVILLE MA 02144 042103634 501(C)(3) 140553 0 RESEARCH & DEVELOPMENT TULANE UNIVERSITY THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND 6823 ST CHARLES AV NEW ORLEANS LA 70118 720423889 501(C)(3) 138082 0 RESEARCH & DEVELOPMENT THE BRIGHAM AND WOMEN'S HOPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 128516 0 RESEARCH & DEVELOPMENT FRED HUTCHINSON CANCER RESEACH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 125001 0 RESEARCH & DEVELOPMENT GEORGE WASHINGTON UNIVERSITY 45155 RESEARCH PLACE - STE 160 ASHBURN VA 20147 530196584 501(C)(3) 117381 0 RESEARCH & DEVELOPMENT THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER SA 7703 FLOYD CURL DRIVE SAN ANTONIO TX 782293900 741586031 501(C)(3) 71900 0 RESEARCH & DEVELOPMENT APPLIED BIOMEDICAL SCIENCE INSTITUTE APPLIED BIOMEDICAL SCIENCE INSTITUTE SAN DIEGO CA 92127 825056708 501(C)(3) 70933 0 RESEARCH & DEVELOPMENT PATH 445 MASSACHUSETTS AVENUE NW STE 1000 WASHINGTON DC 20001 911157127 501(C)(3) 64068 0 RESEARCH & DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 56963 0 RESEARCH & DEVELOPMENT NC STATE TREASURER 3200 ATLANTIC AVE RALEIGH NC 27604 561545517 GOV'T 41470 0 RESEARCH & DEVELOPMENT UNIVERSITY OF WASHINGTON 9750 3RD AVE NE SUITE 400 SEATTLE WA 98115 916001537 501(C)(3) 32490 0 RESEARCH & DEVELOPMENT 22 3 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. REVIEW OF 2 CFR 200 AUDITS AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. X X X X 1 0 0 0 0 0 0 1 0 MARK B FEINBERG PRESIDENT/CEO 617215 0 59460 0 42476 0 109168 0 1547 0 829866 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 458567 0 42520 0 30000 0 54567 0 24701 0 610355 0 0 0 LOUIS D SCHWARTZ ASST. SEC. & CFAO 330037 0 30549 0 30000 0 40367 0 36153 0 467106 0 0 0 SWATI GUPTA VP, HEAD OF EID & EPIDEM. 317567 0 31634 0 30000 0 40597 0 35893 0 455691 0 0 0 DAGNA LAUFER VP & HEAD OF CLINICAL DEV. 333637 0 30551 0 30000 0 39206 0 1942 0 435336 0 0 0 CHRISTOPHER PARKS - ASSOC AVP. VIRAL VAC. & HEAD OF DDL 305862 0 29342 0 30000 0 37656 0 24463 0 427323 0 0 0 SANGEETHA SAGAR VP & HEAD OF PRODUCT DEV 360822 0 7875 0 7350 0 32784 0 720 0 409551 0 0 0 MIN DING GEN. COUNS. & SEC. 276176 0 27810 0 30000 0 35690 0 36153 0 405829 0 0 0 ERIC SKJEVELAND VP, BUSINESS DEVELOPMENT 285620 0 25775 0 30000 0 34650 0 2065 0 378110 0 0 0 FRANCES SINHA FORMER OFFICER 105000 0 0 0 0 0 0 0 0 0 105000 0 0 0 PART I, LINE 4A FRANCES SINHA WAS PAID $105,000 IN SEVERANCE FOR 2023. PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). DESMOND TUTU HIV FOUNDATION AN IAVI BOARD MEMBER IS THE DEPUTY DIRECTOR AND COO OF THE ENTITY. 123104 IAVI HAS A SUB-AWARD AGREEMENT WITH DESMOND TUTU INSTITUTE FOR HIV RESEARCH FOUNDATION. 0 FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND FINANCE COMMITTEE REVIEWED AND APPROVED THE FORM 990 IN DETAIL WITH THE DEPUTY CFO AND CFAO. IT WAS THEN SENT TO THE FULL BOARD BEFORE IT WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD CAN PERIODICALLY COMMISSION A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. WHEN DONE THIS SURVEY COMPARES COMPENSATION PACKAGES OF CEOS OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THEN THE COMMITTEE REVIEWS THE RESULTS AND MAKES RECOMMENDATIONS, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI MAKES USE OF DATA FROM A SPECIALIZED COMPENSATION FIRM TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO, THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATION COMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN DECEMBER 2023. THE COMMITTEE HAD NOT REQUESTED A COMPENSATION SURVEY SPECFIC TO CEO PAY THIS YEAR SO MANAGEMENT REFERENCED EXTENRAL DATA SOURCES TO DETERMINE THE COMPETITIVE LANDSCAPE AND DEVELOP ANNUAL INCREASE RECOMMENDATIONS FOR THE CEO AND OTHER KEY PERSONNEL. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THESE SOURCES AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, IAVI PURCHASES EXTERNAL SALARY SURVEY DATA, AND USES THIS DATA ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. SALARY RECOMMENDATIONS AND EXTERNAL DATA TRENDS MAY BE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVES MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS, RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE GAIN 982,872. CURRENCY TRANSLATION -68,744. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE 0 0 IAVI INC IAVI GLOBAL HEALTH IMPACT LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 FACILITATE PRODUCT DEVELOPMENT AND/OR COMMERCIALIZATION DE 0 0 IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 IAVI SOUTH AFRICA NPC (IAVI-SA) BLACK RIVER PARK 2 FIR ST OBSERVA CAPETOWN SF RESEARCH SUPPORT SF N/A N/A IAVI INC 1 IAVI AFRICA LIMITED 11TH FL MUTHANGARI DR PO BOX 340 NAIROBI KE RESEARCH SUPPORT KE N/A N/A IAVI INC 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 STICHTING IAVI B 3186672 ACTUAL IAVI-SA B 2492212 ACTUAL STICHTING IAVI C 26860 ACTUAL IAVI AFRICA B 2226160 ACTUAL IAVI-INDIA C 27232 ACTUAL